Simcere Partners with AbbVie on Key Drug Candidate SIM0500

Simcere Pharmaceutical Group Limited ( (HK:2096) ) has shared an announcement.

Simcere Pharmaceutical Group Limited announced a licensing agreement with AbbVie for SIM0500, a trispecific antibody drug candidate for multiple myeloma. The agreement allows AbbVie to license the drug outside Greater China, with potential payments to Simcere reaching $1.055 billion, highlighting Simcere’s strategic move to strengthen its global presence and innovation in oncology therapeutics.

More about Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company focusing on therapeutic areas such as neuroscience, anti-oncology, autoimmune, and anti-infection. The company aims to address significant future clinical needs with its advanced drug development, operating a State Key Laboratory of Neurology and Oncology Drug Development. It collaborates with innovative companies and research institutes to enhance its mission of providing future medicines for today’s patients.

YTD Price Performance: -7.61%

Average Trading Volume: 5,721,889

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$16.58B

For an in-depth examination of 2096 stock, go to TipRanks’ Stock Analysis page.